Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Infectious Diseases, Cancer, Obesity), Usage Pattern (Immunization), Administration (Skin, Musculoskeletal), End Users (Hospital, Home Care) & Region - Global Forecast to 2030

icon1
USD 1034.78
MARKET SIZE, 2030
icon2
CAGR 8.4%
(2025-2030)
icon3
900
REPORT PAGES
icon4
120
MARKET TABLES

OVERVIEW

injectable-drug-delivery-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The injectable drug delivery market is projected to reach USD 1,034.78 billion by 2030 from USD 690.23 billion in 2025, at a CAGR of 8.4% from 2025 to 2030. Injectable drug delivery is a method through which a drug is administered to the body via different routes. It could be through the skin, organ, central nervous system, or circulatory/musculoskeletal system. The market growth is fueled by the rising prevalence of chronic diseases, such as diabetes, cancer, and autoimmune disorders, alongside an increasing global demand for biologics.

KEY TAKEAWAYS

  • BY PRODUCT
    Based on type, the injectable drug delivery market is segmented into devices and formulations. The formulations segment accounted for the largest share, driven by the growing use of biologics and biosimilars, which necessitate parenteral administration for efficacy and stability. Moreover, the rising global incidence of chronic and infectious diseases, especially in areas such as oncology, diabetes, autoimmune disorders, and hormonal imbalances, has increased the demand for high-potency, fast-acting injectable formulations.
  • BY THERAPEUTIC APPLICATION
    By therapeutic application, the injectable drug delivery market is segmented into autoimmune diseases, hormonal disorders, obesity, cancer, infectious diseases, orphan diseases, and other therapeutic applications. The autoimmune diseases segment held the largest share owing to the rising prevalence of conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease, along with the growing adoption of biologics and monoclonal antibodies that require injectable administration. Moreover, the availability of advanced self-injection devices like auto-injectors and prefilled syringes, and the strong pipeline of novel biologic therapies further supported the dominance of this segment.
  • BY FORMULATION PACKAGING
    Based on formulation packaging, the market is divided into ampoules, vials, cartridges, and bottles. The ampoules segment is witnessing significant growth due to their superior sterility, affordability, and adaptability to a wide range of drug formulations. Typically made of glass or plastic, ampoules are ideal for preserving single-dose injectable solutions without the risk of contamination, making them highly preferred in acute care and hospital settings. In developing economies such as India, Brazil, and Vietnam, the cost-effectiveness of ampoules encourages their widespread use in government vaccination and immunization programs, thereby further accelerating the growth of this segment.
  • BY USAGE PATTERN
    By usage pattern, the market is further segmented into curative care, immunization, and other usage patterns. The curative care segment leads the market due to the rising prevalence of chronic and infectious diseases. Curative care focuses on treating infectious and chronic diseases through life-saving injectable therapies such as antibiotics, oncology drugs, and cardiovascular treatments. In addition, its widespread adoption across hospitals and clinics continues to drive its dominance in the market.
  • BY SITE OF ADMINISTRATION
    Based on the site of administration, the market is segmented into dermal-based administration, circulatory/musculoskeletal system-based administration, organ-based administration, and central nervous system-based administration (CNS). The dermal-based administration segment held the largest share, attributed to the ease of administration and high efficacy of skin-based administration of vaccines and drugs such as insulin and morphine.
  • BY END USER
    By end user segment, the market is categorized into hospitals & clinics, home care settings, long-term care settings, nursing homes, and other end users. The hospitals & clinics represented the largest share of the injectable drug delivery market in 2024 due to the high volume of inpatient and outpatient procedures requiring rapid, controlled drug administration. This clinical setting ensures precision in dosing, sterility, and managing complex therapies such as chemotherapy, biologics, and critical care drugs. Additionally, the rising burden of chronic conditions has further driven the market growth.
  • BY REGION
    The injectable drug delivery market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is expected to grow at the highest CAGR globally during the forecast period. This growth is primarily driven by the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions in the region. The aging population further contributes to this trend. Significant investments in the healthcare sector are being made in China, India, and Southeast Asia, which facilitate the development of hospitals, clinics, and healthcare facilities. Supportive government policies and regulations also play a vital role in the growth of this region.
  • ECOSYSTEM DYNAMICS
    The major market players have adopted both organic and inorganic strategies, including partnerships and collaborations. For instance, BD announced a strategic collaboration with Ypsomed to advance self-injection solutions for high-viscosity biologic drugs.

The injectable drug delivery market was valued at USD 633.77 billion in 2024 and is projected to grow from USD 690.23 billion in 2025 to USD 1,034.78 billion by 2030, at a CAGR of 8.4% during the forecast period.

MARKET DYNAMICS

Drivers
Impact
Level
  • DRIVERS
  • Growing demand for self-injection devices and advancements in drug delivery technologies
RESTRAINTS
Impact
Level
  • RESTRAINTS
  • Infections associated with needlestick injuries
OPPORTUNITIES
Impact
Level
  • OPPORTUNITIES
  • Development of novel drug delivery systems
CHALLENGES
Impact
Level
  • CHALLENGES
  • Alternative methods of drug delivery

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Growing demand for self-injection devices and advancements in drug delivery technologies

The growing demand for self-injection devices is fueled by increasing patient preference for at-home care and advancements in drug administration technology. The increasing adoption of GLP-1 receptor agonists such as Ozempic and Wegovy by Novo Nordisk A/S for obesity and diabetes management has significantly boosted the need for user-friendly auto-injectors and prefilled pens. Moreover, the emergence of needle-free injectors, which use high-pressure jets or other mechanisms to deliver medication through the skin without the need for a traditional needle, further drives the market growth. This technology alleviates needle phobia and minimizes the risk of needlestick injuries and cross-contamination.

Restraint: Infections associated with needlestick injuries

Needlestick injuries are significantly affecting the growth of the injectable drug delivery market. These injuries are a major occupational hazard for healthcare professionals like nurses, doctors, and technicians, who can result in the transmission of blood-borne pathogens such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Healthcare workers are at a higher risk due to the frequent use of needles and potential exposure to contaminated blood and bodily fluids. According to the CDC, approximately 385,000 healthcare professionals accidentally stab themselves with needles each year. Consequently, infections associated with needlestick injuries tend to hinder market growth.

Opportunity: Development of novel drug delivery systems

Innovations in injectable drug delivery technologies are transforming the market by enhancing treatment efficacy, safety, and patient compliance. Recent developments in devices, such as microneedles and needle-free injectors provide painless, self-administration alternatives to traditional injections. This helps enhance patient compliance. Smart injectables with sensors and controlled-release systems also allow personalized treatments, offering patient-friendly treatment options and accelerating market growth.

Challenge: Complexities in developing wearable drug delivery systems

The growth of the injectable drug delivery market is significantly hindered by several technical challenges associated with the development of large-volume on-body injectors (OBIs), particularly in the subcutaneous (SC) delivery of biologics. The increasing demand for SC injections capable of administering larger volumes, beyond the traditional limits of 1 mL, complicates drug formulation and device compatibility.

INJECTABLE DRUG DELIVERY MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Prefilled syringes for vaccines and biologics Reduced contamination risk, precise dosing, enhanced patient safety
Self-injection wearable injectors for chronic diseases Improved patient adherence, at-home treatment convenience, reduced hospital visits
Glass cartridges and syringes for insulin delivery systems High chemical resistance, compatibility with sensitive biologics
Insulin pens and prefilled devices for diabetes management Accurate micro-dosing, user-friendly devices, better glycemic control
Disposable autoinjectors for biologics and biosimilars Single-use safety, minimal training required, consistent dosing

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The injectable drug delivery market ecosystem comprises manufacturers, suppliers, healthcare providers, regulatory bodies, and end users. Manufacturers are central to the ecosystem and depend on suppliers for components such as prefilled syringes, autoinjectors, vials, and cartridges. Suppliers provide critical raw materials. Healthcare providers, including hospitals & clinics and home care settings, are major users of injectable drug delivery systems. They require high levels of accuracy, sterility, and ease of use to ensure safe administration and optimal therapeutic outcomes. Regulatory agencies such as the FDA (US), EMA (Europe), and PMDA (Japan) play a vital role by enforcing guidelines related to product safety, quality, and efficacy.

injectable-drug-delivery-market Ecosystem

 

Injectable Drug Delivery Market, By Product

The formulations segment represents the largest segment of the injectable drug delivery market, driven by the growing use of biologics and biosimilars, which necessitate parenteral administration for both efficacy and stability. Moreover, the rising global incidence of chronic and infectious diseases, especially in areas such as oncology, diabetes, autoimmune disorders, and hormonal imbalances, has increased the demand for high-potency, fast-acting injectable formulations. The US, China, Germany, and India are experiencing a significant rise in the use of monoclonal antibodies, insulin analogs, and long-acting injectables, further enhancing the growth of this market segment.

Injectable Drug Delivery Market, By Formulation Packaging

The ampoules segment is the fastest-growing packaging segment in the injectable drug delivery market, driven by their superior sterility, affordability, and adaptability to a wide range of drug formulations. Typically made of glass or plastic, ampoules are ideal for preserving single-dose injectable solutions without the risk of contamination, making them highly preferred in acute care and hospital settings. Moreover, in developing economies such as India, Brazil, and Vietnam, the cost-effectiveness of ampoules encourages their widespread use in government vaccination and immunization programs, further accelerating this segment's growth.

Injectable Drug Delivery Market, By Usage Pattern

The curative care segment holds the largest share in the injectable drug delivery market by usage pattern, as it focuses on treating infectious and chronic diseases through life-saving injectable therapies such as antibiotics, oncology drugs, and cardiovascular treatments. Its widespread adoption across hospitals and clinics and the rising prevalence of chronic and infectious conditions worldwide continue to drive its dominance in the market.

Injectable Drug Delivery Market, By End User

Hospitals & clinics represent the largest share of the injectable drug delivery market in 2024 due to the high volume of inpatient and outpatient procedures requiring rapid, controlled drug administration. This clinical setting ensures precision in dosing, sterility, and management of complex therapies such as chemotherapy, biologics, and critical care drugs. Additionally, the rising burden of chronic conditions, particularly cancer, diabetes, and autoimmune diseases, has driven the demand for specialized treatments administered under medical supervision. Moreover, in countries such as the US, Germany, and Japan, high healthcare expenditures and strong institutional infrastructure support the use of advanced injectable systems in hospital settings.

REGION

Asia Pacific to be fastest-growing region in global injectable drug delivery market during forecast period

The Asia Pacific is expected to grow at the highest CAGR globally during the forecast period. This growth is primarily driven by the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions in the region. The aging population further contributes to this trend. Significant investments in the healthcare sector are being made in China, India, and Southeast Asia, which facilitate the development of hospitals, clinics, and healthcare facilities. Supportive government policies and regulations also play a vital role in the growth of this segment.

injectable-drug-delivery-market Region

INJECTABLE DRUG DELIVERY MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMPANY EVALUATION MATRIX

In the injectable drug delivery market matrix, Cardinal Health (Star) leads with scale, extensive distribution, and a broad solutions portfolio. Stevanato Group (Emerging Leader) is gaining momentum with innovative prefilled syringes and packaging technologies. While Cardinal Health dominates through reach, Stevanato’s innovation positions it for rapid growth toward the leaders’ quadrant.

injectable-drug-delivery-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 633.77 BN
Market Forecast in 2030 (Value) USD 1,034.78 BN
Growth Rate CAGR of 8.4% from 2025 to 2030
Years Considered 2023–2030
Base Year 2024
Forecast Period 2025–2030
Units Considered Value (USD BN)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered •       By Product: Devices and Formulations
Regional Scope North America, Asia Pacific, Europe, Latin America, and Middle East & Africa

WHAT IS IN IT FOR YOU: INJECTABLE DRUG DELIVERY MARKET: GROWTH, SIZE, SHARE, AND TRENDS REPORT CONTENT GUIDE

injectable-drug-delivery-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis Comparison of top injectable delivery devices: Prefilled syringes, Auto-injectors, and Wearable injectors Identify interconnections and supply chain blind spots; Detect customer migration trends across industries
Company Information Key players: BD (Becton Dickinson), West Pharmaceutical, Gerresheimer, Schott AG, Novo Nordisk, Ypsomed; Top 3–5 players market share analysis at the country-level of the Asia Pacific and Europe regions Insights on revenue shifts towards emerging therapeutic applications and device innovations
Geographic Analysis Detailed analysis on the Rest of Asia Pacific for top players; Client focused on the ASEAN market, country-level analysis for the device market Country-level demand mapping for new product launches and localization strategy planning

RECENT DEVELOPMENTS

  • Mar-25 : Johnson & Johnson Services, Inc. received US FDA approval for TREMFYA, the first and only IL-23 inhibitor, offering subcutaneous and intravenous induction options for adult patients with Crohn’s disease.
  • Jaunuay 2025 : Terumo Corporation announced the global launch of the Terumo Injection Filter Needle, marking the first step in the INFINO Development Program. Designed for hypodermic and intravitreal injections, the injection filter features an integrated 5-micrometer mesh filter that prevents the injection of particles.
  • Dec-24 : Gerresheimer announced that the US FDA granted tentative approval for SQ Innovation's Lasix ONYU, which is intended for home treatment of fluid overload in patients with congestive heart failure. Lasix ONYU is a combination product with a new high-concentration formulation of the diuretic furosemide and Gerresheimer's on-body drug delivery device.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
72
2
RESEARCH METHODOLOGY
 
 
 
 
 
78
3
EXECUTIVE SUMMARY
 
 
 
 
 
93
4
PREMIUM INSIGHTS
 
 
 
 
 
99
5
MARKET OVERVIEW
Surging demand for self-injection devices drives innovation amid regulatory and safety challenges.
 
 
 
 
 
102
 
5.1
MARKET DYNAMICS
 
 
 
 
 
 
 
5.1.1
DRIVERS
 
 
 
 
 
 
 
5.1.1.1
GROWING DEMAND FOR SELF-INJECTION DEVICES
 
 
 
 
 
 
5.1.1.2
ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
 
 
 
 
 
 
5.1.1.3
RISING PREVALENCE OF CHRONIC DISEASES
 
 
 
 
 
 
5.1.1.4
GROWING ADOPTION OF BIOLOGICS AND BIOSIMILARS
 
 
 
 
 
5.1.2
RESTRAINTS
 
 
 
 
 
 
 
5.1.2.1
INFECTIONS ASSOCIATED WITH NEEDLESTICK INJURIES
 
 
 
 
 
 
5.1.2.2
STRINGENT GOVERNMENT REGULATIONS
 
 
 
 
 
5.1.3
OPPORTUNITIES
 
 
 
 
 
 
 
5.1.3.1
DEVELOPMENT OF NOVEL DRUG DELIVERY SYSTEMS
 
 
 
 
 
 
5.1.3.2
GROWING PREFERENCE FOR HOME-BASED CARE DEVICES
 
 
 
 
 
 
5.1.3.3
GROWTH OPPORTUNITIES IN EMERGING ECONOMIES
 
 
 
 
 
5.1.4
CHALLENGES
 
 
 
 
 
 
 
5.1.4.1
ALTERNATIVE METHODS OF DRUG DELIVERY
 
 
 
 
 
 
5.1.4.2
COMPLEXITIES IN DEVELOPING WEARABLE DRUG DELIVERY SYSTEMS
 
 
 
 
5.2
INDUSTRY TRENDS
 
 
 
 
 
 
 
5.2.1
REUSABLE DRUG DELIVERY DEVICES
 
 
 
 
 
 
5.2.2
PREFILLED BIOLOGICS
 
 
 
 
 
5.3
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
5.4
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.4.1
AVERAGE SELLING PRICE TREND, BY KEY PLAYER
 
 
 
 
 
 
 
5.4.1.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY DEVICE TYPE
 
 
 
 
 
 
5.4.1.2
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PEN INJECTORS
 
 
 
 
 
5.4.2
AVERAGE SELLING PRICE TREND, BY REGION
 
 
 
 
 
 
 
5.4.2.1
AVERAGE SELLING PRICE TREND OF PEN INJECTORS, BY REGION
 
 
 
 
 
 
5.4.2.2
AVERAGE SELLING PRICE TREND OF NEEDLE-FREE INJECTORS, BY REGION
 
 
 
 
 
 
5.4.2.3
AVERAGE SELLING PRICE TREND OF AUTOINJECTORS, BY REGION
 
 
 
 
 
 
5.4.2.4
AVERAGE SELLING PRICE TREND OF WEARABLE INJECTORS, BY REGION
 
 
 
 
5.5
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
RESEARCH & PRODUCT DEVELOPMENT
 
 
 
 
 
 
5.5.2
RAW MATERIAL PROCUREMENT
 
 
 
 
 
 
5.5.3
MANUFACTURING
 
 
 
 
 
 
5.5.4
MARKETING, SALES & DISTRIBUTION, AND AFTER-SALES SERVICES
 
 
 
 
 
5.6
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
 
5.7
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.8
INVESTMENT AND FUNDING SCENARIO
 
 
 
 
 
 
5.9
TECHNOLOGY ANALYSIS
 
 
 
 
 
 
 
5.9.1
KEY TECHNOLOGIES
 
 
 
 
 
 
 
5.9.1.1
AUTOINJECTORS AND SMART INJECTION DEVICES
 
 
 
 
 
 
5.9.1.2
NEEDLE-FREE INJECTION SYSTEMS AND MICRONEEDLE PATCHES
 
 
 
 
 
 
5.9.1.3
WEARABLE INJECTORS FOR HIGH-VOLUME DELIVERY
 
 
 
 
 
5.9.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
5.9.2.1
NANOTECHNOLOGY
 
 
 
 
 
 
5.9.2.2
BIODEGRADABLE POLYMERS
 
 
 
 
 
5.9.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
5.9.3.1
ARTIFICIAL INTELLIGENCE AND DIGITAL THERAPEUTICS
 
 
 
 
 
 
5.9.3.2
ALTERNATIVE ROUTES OF ADMINISTRATION
 
 
 
 
5.10
PATENT ANALYSIS
 
 
 
 
 
 
 
 
5.10.1
PATENT PUBLICATION TRENDS FOR INJECTABLE DRUG DELIVERY
 
 
 
 
 
 
5.10.2
JURISDICTION AND TOP APPLICANT ANALYSIS
 
 
 
 
 
5.11
TRADE ANALYSIS
 
 
 
 
 
 
 
 
5.11.1
TRADE DATA FOR HS CODE 901890
 
 
 
 
 
 
 
5.11.1.1
IMPORT DATA
 
 
 
 
 
 
5.11.1.2
EXPORT DATA
 
 
 
 
 
5.11.2
TRADE DATA FOR HS CODE 90183100
 
 
 
 
 
 
 
5.11.2.1
IMPORT DATA
 
 
 
 
 
 
5.11.2.2
EXPORT DATA
 
 
 
 
5.12
KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
 
5.13
CASE STUDY ANALYSIS
 
 
 
 
 
 
5.14
REGULATORY LANDSCAPE
 
 
 
 
 
 
 
5.14.1
REGULATORY ANALYSIS
 
 
 
 
 
 
5.14.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
5.15
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.15.1
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.15.2
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.15.3
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.15.4
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.15.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.16
KEY STAKEHOLDERS AND BUYING CRITERIA
 
 
 
 
 
 
 
 
5.16.1
KEY STAKEHOLDERS
 
 
 
 
 
 
5.16.2
BUYING CRITERIA
 
 
 
 
 
 
 
5.16.2.1
BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY DEVICES
 
 
 
 
 
 
5.16.2.2
BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY DEVICES WITH FORMULATIONS
 
 
 
 
5.17
PIPELINE ANALYSIS
 
 
 
 
 
 
5.18
REIMBURSEMENT ANALYSIS
 
 
 
 
 
 
5.19
UNMET NEEDS/END-USER EXPECTATIONS
 
 
 
 
 
 
5.20
IMPACT OF AI/GEN AI IN INJECTABLE DRUG DELIVERY MARKET
 
 
 
 
 
 
 
 
5.20.1
INTRODUCTION
 
 
 
 
 
 
5.20.2
MARKET POTENTIAL OF AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
 
 
 
 
 
 
5.20.3
AI USE CASES
 
 
 
 
 
 
5.20.4
KEY COMPANIES IMPLEMENTING AI IN INJECTABLE DRUG DELIVERY DEVICES
 
 
 
 
 
 
5.20.5
FUTURE OF GEN AI IN INJECTABLE DRUG DELIVERY ECOSYSTEM
 
 
 
 
 
5.21
IMPACT OF 2025 US TARIFF
 
 
 
 
 
 
 
 
5.21.1
INTRODUCTION
 
 
 
 
 
 
5.21.2
KEY TARIFF RATES
 
 
 
 
 
 
5.21.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.21.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.21.4.1
NORTH AMERICA
 
 
 
 
 
 
5.21.4.2
ASIA PACIFIC
 
 
 
 
 
 
5.21.4.3
EUROPE
 
 
 
 
 
 
5.21.4.4
LATIN AMERICA
 
 
 
 
 
5.21.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
6
INJECTABLE DRUG DELIVERY, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion and Units | 138 Data Tables
 
 
 
 
 
159
 
6.1
INTRODUCTION
 
 
 
 
 
 
6.2
DEVICES
 
 
 
 
 
 
 
6.2.1
CONVENTIONAL INJECTION DEVICES
 
 
 
 
 
 
 
6.2.1.1
BY MATERIAL
 
 
 
 
 
 
 
 
6.2.1.1.1
GLASS INJECTABLE DEVICES
 
 
 
 
 
 
6.2.1.1.2
PLASTIC INJECTABLE DEVICES
 
 
 
 
6.2.1.2
BY PRODUCT
 
 
 
 
 
 
 
 
6.2.1.2.1
FILLABLE SYRINGES
 
 
 
 
 
 
6.2.1.2.2
PREFILLED SYRINGES
 
 
 
 
6.2.1.3
BY USABILITY
 
 
 
 
 
 
 
 
6.2.1.3.1
REUSABLE INJECTION DEVICES
 
 
 
 
 
 
6.2.1.3.2
DISPOSABLE INJECTION DEVICES
 
 
 
6.2.2
SELF-INJECTION DEVICES
 
 
 
 
 
 
 
6.2.2.1
NEEDLE-FREE INJECTORS
 
 
 
 
 
 
 
 
6.2.2.1.1
BY PRODUCT
 
 
 
 
 
 
6.2.2.1.2
BY TECHNOLOGY
 
 
 
 
 
 
6.2.2.1.3
BY USABILITY
 
 
 
 
6.2.2.2
AUTOINJECTORS
 
 
 
 
 
 
 
 
6.2.2.2.1
BY PRODUCT
 
 
 
 
 
 
6.2.2.2.2
BY TECHNOLOGY
 
 
 
 
 
 
6.2.2.2.3
BY DESIGN
 
 
 
 
 
 
6.2.2.2.4
BY USABILITY
 
 
 
 
6.2.2.3
PEN INJECTORS
 
 
 
 
 
 
 
 
6.2.2.3.1
BY PRODUCT
 
 
 
 
 
 
6.2.2.3.2
BY DESIGN
 
 
 
 
 
 
6.2.2.3.3
BY USABILITY
 
 
 
 
6.2.2.4
WEARABLE INJECTORS
 
 
 
 
 
 
 
 
6.2.2.4.1
INCREASING NEED FOR SAFE AND CONVENIENT INJECTIONS TO ACCELERATE GROWTH
 
 
 
 
6.2.2.5
OTHER SELF-INJECTION DEVICES
 
 
 
 
6.3
FORMULATIONS
 
 
 
 
 
 
 
6.3.1
CONVENTIONAL DRUG DELIVERY FORMULATIONS
 
 
 
 
 
 
 
6.3.1.1
SOLUTIONS
 
 
 
 
 
 
 
 
6.3.1.1.1
HIGH STABILITY AND STERILITY BENEFITS TO INTENSIFY GROWTH
 
 
 
 
6.3.1.2
RECONSTITUTED/LYOPHILIZED FORMULATIONS
 
 
 
 
 
 
 
 
6.3.1.2.1
HIGHER SUITABILITY FOR PARENTERAL ADMINISTRATION TO AID GROWTH
 
 
 
 
6.3.1.3
SUSPENSIONS
 
 
 
 
 
 
 
 
6.3.1.3.1
INNOVATIONS IN INJECTABLE SUSPENSIONS FOR STABLE AND SUSTAINED DELIVERY TO AID GROWTH
 
 
 
 
6.3.1.4
EMULSIONS
 
 
 
 
 
 
 
 
6.3.1.4.1
ADVANCEMENTS IN INJECTABLE EMULSIONS FOR CONTROLLED AND SUSTAINED DRUG DELIVERY TO DRIVE MARKET
 
 
 
6.3.2
NOVEL DRUG DELIVERY FORMULATIONS
 
 
 
 
 
 
 
6.3.2.1
COLLOIDAL DISPERSIONS
 
 
 
 
 
 
 
 
6.3.2.1.1
NIOSOMES
 
 
 
 
 
 
6.3.2.1.2
LIPOSOMES
 
 
 
 
 
 
6.3.2.1.3
POLYMERIC/MIXED MICELLES
 
 
 
 
 
 
6.3.2.1.4
NANOPARTICLES
 
 
 
 
6.3.2.2
MICROPARTICLES
 
 
 
 
 
 
 
 
6.3.2.2.1
MICROSPHERES
 
 
 
 
 
 
6.3.2.2.2
MICROCAPSULES
 
 
 
6.3.3
LONG-ACTING INJECTABLE FORMULATIONS
 
 
 
 
 
 
 
6.3.3.1
DECREASED SIDE EFFECTS AND OVERALL MEDICAL COST REDUCTION TO ADVANCE GROWTH
 
 
 
7
INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 5 Data Tables
 
 
 
 
 
287
 
7.1
INTRODUCTION
 
 
 
 
 
 
7.2
AMPOULES
 
 
 
 
 
 
 
7.2.1
EASE OF TRANSPORTATION AND LOW MANUFACTURING COST TO AID GROWTH
 
 
 
 
 
7.3
VIALS
 
 
 
 
 
 
 
7.3.1
NEED FOR SECURE, DEPENDABLE, AND COST-EFFECTIVE CONTAINERS TO ENCOURAGE GROWTH
 
 
 
 
 
7.4
CARTRIDGES
 
 
 
 
 
 
 
7.4.1
INCREASING FOCUS ON DOSE ACCURACY AND PATIENT CONVENIENCE TO FACILITATE GROWTH
 
 
 
 
 
7.5
BOTTLES
 
 
 
 
 
 
 
7.5.1
RISING FOCUS ON SAFE STORAGE OF SOLUTIONS AND EMULSIONS TO FOSTER GROWTH
 
 
 
 
8
INJECTABLE DRUG DELIVERY, BY THERAPEUTIC APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 47 Data Tables
 
 
 
 
 
296
 
8.1
INTRODUCTION
 
 
 
 
 
 
8.2
AUTOIMMUNE DISEASES
 
 
 
 
 
 
 
8.2.1
RHEUMATOID ARTHRITIS
 
 
 
 
 
 
 
8.2.1.1
INCREASED FOCUS ON EARLY-STAGE DIAGNOSIS AND TREATMENT TO AMPLIFY GROWTH
 
 
 
 
 
8.2.2
MULTIPLE SCLEROSIS
 
 
 
 
 
 
 
8.2.2.1
INCREASING TARGET PATIENT POOL TO CONTRIBUTE TO GROWTH
 
 
 
 
 
8.2.3
CROHN’S DISEASE
 
 
 
 
 
 
 
8.2.3.1
RISING USE OF LIPOSOMES TO AID GROWTH
 
 
 
 
 
8.2.4
PSORIASIS
 
 
 
 
 
 
 
8.2.4.1
LIFESTYLE CHANGES AND HIGH DISEASE PREVALENCE TO SUPPORT GROWTH
 
 
 
 
 
8.2.5
OTHER AUTOIMMUNE DISEASES
 
 
 
 
 
8.3
HORMONAL DISORDERS
 
 
 
 
 
 
 
8.3.1
DIABETES
 
 
 
 
 
 
 
8.3.1.1
GROWING PREFERENCE FOR SELF-INJECTION DEVICES OVER TRADITIONAL SYRINGES TO DRIVE MARKET
 
 
 
 
 
8.3.2
REPRODUCTIVE HEALTH DISEASES
 
 
 
 
 
 
 
8.3.2.1
LACK OF HEALTHCARE FACILITIES AND HYGIENE PRACTICES TO AID GROWTH
 
 
 
 
 
8.3.3
ANTITHROMBOTIC/THROMBOLYTIC THERAPY
 
 
 
 
 
 
 
8.3.3.1
HIGH EFFICACY AND SAFETY OF HEPARIN FOR ANTITHROMBOTIC THERAPY TO AID GROWTH
 
 
 
 
 
8.3.4
OSTEOPOROSIS
 
 
 
 
 
 
 
8.3.4.1
INCREASING NUMBER OF WOMEN WITH CALCIUM AND VITAMIN D DEFICIENCIES TO FOSTER GROWTH
 
 
 
 
 
8.3.5
GROWTH HORMONE DEFICIENCY
 
 
 
 
 
 
 
8.3.5.1
INCREASED NEED FOR DAILY INJECTIONS OF RECOMBINANT HUMAN GROWTH HORMONES TO FUEL MARKET
 
 
 
 
8.4
OBESITY
 
 
 
 
 
 
 
8.4.1
CHANGING SEDENTARY LIFESTYLE AND CONSUMPTION OF OVER-PROCESSED FOODS TO AID GROWTH
 
 
 
 
 
8.5
CANCER
 
 
 
 
 
 
 
8.5.1
INCREASING LAUNCHES OF NEW VACCINES AND TARGETED THERAPIES TO BOLSTER GROWTH
 
 
 
 
 
8.6
INFECTIOUS DISEASES
 
 
 
 
 
 
 
8.6.1
GROWING ADVANCEMENTS IN INJECTABLE THERAPIES TO DRIVE MARKET
 
 
 
 
 
8.7
ORPHAN DISEASES
 
 
 
 
 
 
 
8.7.1
FAVORABLE GOVERNMENT INITIATIVES TO AUGMENT GROWTH
 
 
 
 
 
8.8
OTHER THERAPEUTIC APPLICATIONS
 
 
 
 
 
 
 
8.8.1
PAIN MANAGEMENT
 
 
 
 
 
 
 
8.8.1.1
GROWING FOCUS ON TREATING CHRONIC PAIN TO DRIVE MARKET
 
 
 
 
 
8.8.2
ALLERGIES
 
 
 
 
 
 
 
8.8.2.1
INCREASING PREVALENCE OF ASTHMA AND ECZEMA TO PROMOTE GROWTH
 
 
 
 
 
8.8.3
AESTHETIC TREATMENTS
 
 
 
 
 
 
 
8.8.3.1
GROWING POPULARITY OF AESTHETIC PROCEDURES TO PROPEL MARKET
 
 
 
 
 
8.8.4
HEPATITIS C
 
 
 
 
 
 
 
8.8.4.1
NEED TO CURB VIRUS SPREAD DUE TO NEEDLE RESHARE TO SUSTAIN GROWTH
 
 
 
 
 
8.8.5
HEMOPHILIA
 
 
 
 
 
 
 
8.8.5.1
INCREASING NEED FOR PREVENTIVE TREATMENT PLANS TO ASSIST GROWTH
 
 
 
9
INJECTABLE DRUG DELIVERY, BY USAGE PATTERN
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 4 Data Tables
 
 
 
 
 
345
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
CURATIVE CARE
 
 
 
 
 
 
 
9.2.1
RISE IN INFECTIOUS DISEASES TO ACCELERATE GROWTH
 
 
 
 
 
9.3
IMMUNIZATION
 
 
 
 
 
 
 
9.3.1
GROWING DEMAND FOR VACCINES FROM HEALTHCARE ORGANIZATIONS TO DRIVE MARKET
 
 
 
 
 
9.4
OTHER USAGE PATTERNS
 
 
 
 
 
10
INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 9 Data Tables
 
 
 
 
 
352
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
DERMAL-BASED ADMINISTRATION
 
 
 
 
 
 
 
10.2.1
RAPID AND EFFECTIVE METHOD WITH LOW PAIN TO AMPLIFY GROWTH
 
 
 
 
 
10.3
CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
 
 
 
 
 
 
 
10.3.1
HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT GROWTH
 
 
 
 
 
10.4
ORGAN-BASED ADMINISTRATION
 
 
 
 
 
 
 
10.4.1
GROWING UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST MARKET
 
 
 
 
 
10.5
CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
 
 
 
 
 
 
 
10.5.1
INCREASING FOCUS ON PAIN MANAGEMENT TO PROMOTE GROWTH
 
 
 
 
11
INJECTABLE DRUG DELIVERY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 6 Data Tables
 
 
 
 
 
363
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
HOSPITALS & CLINICS
 
 
 
 
 
 
 
11.2.1
RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
 
 
 
 
 
11.3
HOME CARE SETTINGS
 
 
 
 
 
 
 
11.3.1
GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET
 
 
 
 
 
11.4
LONG-TERM CARE SETTINGS
 
 
 
 
 
 
 
11.4.1
BOOMING ELDERLY POPULATION AND BURDEN OF CHRONIC DISEASES TO EXPEDITE GROWTH
 
 
 
 
 
11.5
NURSING HOMES
 
 
 
 
 
 
 
11.5.1
GLOBAL SHIFT TOWARD AGED POPULATION TO STIMULATE GROWTH
 
 
 
 
 
11.6
OTHER END USERS
 
 
 
 
 
12
INJECTABLE DRUG DELIVERY MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 20 Countries | 926 Data Tables.
 
 
 
 
 
374
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
NORTH AMERICA
 
 
 
 
 
 
 
12.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
 
 
12.2.2
US
 
 
 
 
 
 
 
12.2.2.1
INCREASING PREVALENCE OF CHRONIC DISEASES TO EXPEDITE GROWTH
 
 
 
 
 
12.2.3
CANADA
 
 
 
 
 
 
 
12.2.3.1
GROWING PREFERENCE FOR SELF-INJECTION DEVICES TO DRIVE MARKET
 
 
 
 
12.3
EUROPE
 
 
 
 
 
 
 
12.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
 
 
12.3.2
GERMANY
 
 
 
 
 
 
 
12.3.2.1
HIGH HEALTHCARE SPENDING TO PROPEL GROWTH
 
 
 
 
 
12.3.3
UK
 
 
 
 
 
 
 
12.3.3.1
RISING CASES OF OBESITY AND DIABETES TO PROMOTE GROWTH
 
 
 
 
 
12.3.4
FRANCE
 
 
 
 
 
 
 
12.3.4.1
FAVORABLE HEALTH INSURANCE SYSTEM TO ACCELERATE GROWTH
 
 
 
 
 
12.3.5
SPAIN
 
 
 
 
 
 
 
12.3.5.1
FAVORABLE HEALTHCARE REGULATIONS SUPPORT GROWTH
 
 
 
 
 
12.3.6
ITALY
 
 
 
 
 
 
 
12.3.6.1
REGIONAL VARIATION IN TERMS OF COVERAGE AND BENEFITS TO HINDER GROWTH
 
 
 
 
 
12.3.7
NETHERLANDS
 
 
 
 
 
 
 
12.3.7.1
GROWING FOCUS ON ENHANCED PATIENT CARE TO DRIVE MARKET
 
 
 
 
 
12.3.8
REST OF EUROPE
 
 
 
 
 
12.4
ASIA PACIFIC
 
 
 
 
 
 
 
12.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
 
 
12.4.2
CHINA
 
 
 
 
 
 
 
12.4.2.1
LARGE PATIENT POPULATION AND HEALTHCARE INFRASTRUCTURE IMPROVEMENTS TO AUGMENT GROWTH
 
 
 
 
 
12.4.3
JAPAN
 
 
 
 
 
 
 
12.4.3.1
SUPPORTIVE REIMBURSEMENT POLICIES AND UNIVERSAL HEALTHCARE COVERAGE TO AID GROWTH
 
 
 
 
 
12.4.4
INDIA
 
 
 
 
 
 
 
12.4.4.1
RISING DIABETES AND CARDIOVASCULAR DISEASE BURDEN TO PROPEL MARKET
 
 
 
 
 
12.4.5
AUSTRALIA
 
 
 
 
 
 
 
12.4.5.1
INCREASED PATIENT VOLUME TO CONTRIBUTE TO GROWTH
 
 
 
 
 
12.4.6
SOUTH KOREA
 
 
 
 
 
 
 
12.4.6.1
RISING INCIDENCE OF OBESITY AND HYPERTENSION TO AMPLIFY GROWTH
 
 
 
 
 
12.4.7
THAILAND
 
 
 
 
 
 
 
12.4.7.1
EXPANDING SELF-ADMINISTRATION OPTIONS TO SUPPORT GROWTH
 
 
 
 
 
12.4.8
VIETNAM
 
 
 
 
 
 
 
12.4.8.1
RISING INVESTMENTS AND REGULATORY REFORMS TO SUPPORT MARKET GROWTH
 
 
 
 
 
12.4.9
REST OF ASIA PACIFIC
 
 
 
 
 
12.5
LATIN AMERICA
 
 
 
 
 
 
 
12.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
 
 
12.5.2
BRAZIL
 
 
 
 
 
 
 
12.5.2.1
SURGE IN OBESITY ISSUES TO STIMULATE GROWTH
 
 
 
 
 
12.5.3
MEXICO
 
 
 
 
 
 
 
12.5.3.1
INCREASING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
 
 
 
 
 
12.5.4
REST OF LATIN AMERICA
 
 
 
 
 
12.6
MIDDLE EAST & AFRICA
 
 
 
 
 
 
 
12.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
 
 
12.6.2
GCC COUNTRIES
 
 
 
 
 
 
 
12.6.2.1
SAUDI ARABIA
 
 
 
 
 
 
 
 
12.6.2.1.1
HEALTHCARE REFORMS TO CONTRIBUTE TO GROWTH
 
 
 
 
12.6.2.2
UNITED ARAB EMIRATES (UAE)
 
 
 
 
 
 
 
 
12.6.2.2.1
GROWING INFRASTRUCTURE INVESTMENTS TO DRIVE MARKET
 
 
 
 
12.6.2.3
REST OF GCC COUNTRIES
 
 
 
 
 
12.6.3
REST OF MIDDLE EAST & AFRICA
 
 
 
 
13
COMPETITIVE LANDSCAPE
Uncover strategic dominance and emerging leaders in the injectable drug delivery market by 2024.
 
 
 
 
 
769
 
13.1
OVERVIEW
 
 
 
 
 
 
13.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
13.3
REVENUE ANALYSIS, 2020–2024
 
 
 
 
 
 
 
 
13.3.1
INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
 
 
 
 
 
 
13.3.2
INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
 
 
 
 
 
13.4
MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
 
 
 
13.4.1
INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
 
 
 
 
 
 
13.4.2
INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
 
 
 
 
 
13.5
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
 
13.6
R&D EXPENDITURE OF KEY PLAYERS
 
 
 
 
 
 
13.7
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
 
 
 
13.7.1
COMPANY VALUATION
 
 
 
 
 
 
13.7.2
FINANCIAL METRICS
 
 
 
 
 
13.8
INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
 
 
 
 
13.8.1
STARS
 
 
 
 
 
 
13.8.2
EMERGING LEADERS
 
 
 
 
 
 
13.8.3
PERVASIVE PLAYERS
 
 
 
 
 
 
13.8.4
PARTICIPANTS
 
 
 
 
 
 
13.8.5
INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT, 2024
 
 
 
 
 
 
 
13.8.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
13.8.5.2
REGION FOOTPRINT
 
 
 
 
 
 
13.8.5.3
PRODUCT TYPE FOOTPRINT
 
 
 
 
 
 
13.8.5.4
USAGE PATTERN FOOTPRINT
 
 
 
 
 
 
13.8.5.5
THERAPEUTIC APPLICATION FOOTPRINT
 
 
 
 
 
 
13.8.5.6
SITE OF ADMINISTRATION FOOTPRINT
 
 
 
 
13.9
INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
 
 
 
 
13.9.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
13.9.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
13.9.3
DYNAMIC COMPANIES
 
 
 
 
 
 
13.9.4
STARTING BLOCKS
 
 
 
 
 
 
13.9.5
INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024
 
 
 
 
 
 
 
13.9.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
13.9.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
13.10
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
 
 
 
 
13.10.1
STARS
 
 
 
 
 
 
13.10.2
EMERGING LEADERS
 
 
 
 
 
 
13.10.3
PERVASIVE PLAYERS
 
 
 
 
 
 
13.10.4
PARTICIPANTS
 
 
 
 
 
 
13.10.5
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT, 2024
 
 
 
 
 
 
 
13.10.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
13.10.5.2
REGION FOOTPRINT
 
 
 
 
 
 
13.10.5.3
PRODUCT TYPE FOOTPRINT
 
 
 
 
 
 
13.10.5.4
FORMULATION PACKAGING TYPE FOOTPRINT
 
 
 
 
 
 
13.10.5.5
THERAPEUTIC APPLICATION FOOTPRINT
 
 
 
 
 
 
13.10.5.6
SITE OF ADMINISTRATION FOOTPRINT
 
 
 
 
13.11
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
 
 
 
 
 
 
 
 
13.11.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
13.11.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
13.11.3
DYNAMIC COMPANIES
 
 
 
 
 
 
13.11.4
STARTING BLOCKS
 
 
 
 
 
 
13.11.5
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2024
 
 
 
 
 
 
 
13.11.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
13.11.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
13.12
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
13.12.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
 
 
13.12.2
DEALS
 
 
 
 
 
 
13.12.3
EXPANSIONS
 
 
 
 
14
COMPANY PROFILES: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
806
 
14.1
KEY PLAYERS
 
 
 
 
 
 
 
14.1.1
CARDINAL HEALTH
 
 
 
 
 
 
 
14.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
14.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
14.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
14.1.1.3.1
EXPANSIONS
 
 
 
 
14.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
14.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
14.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
14.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
 
 
 
14.1.2
BD
 
 
 
 
 
 
14.1.3
B. BRAUN SE
 
 
 
 
 
 
14.1.4
BAXTER
 
 
 
 
 
 
14.1.5
TERUMO CORPORATION
 
 
 
 
 
 
14.1.6
PHILLIPS-MEDSIZE CORPORATION (MOLEX)
 
 
 
 
 
 
14.1.7
NIPRO
 
 
 
 
 
 
14.1.8
ICU MEDICAL, INC.
 
 
 
 
 
 
14.1.9
WEST PHARMACEUTICAL SERVICES, INC.
 
 
 
 
 
 
14.1.10
GERRESHEIMER AG
 
 
 
 
 
 
14.1.11
STEVANATO
 
 
 
 
 
 
14.1.12
SCHOTT PHARMA
 
 
 
 
 
 
14.1.13
MEDMIX
 
 
 
 
 
 
14.1.14
SOLM
 
 
 
 
 
 
14.1.15
YPSOMED
 
 
 
 
 
14.2
OTHER PLAYERS
 
 
 
 
 
 
 
14.2.1
OWEN MUMFORD
 
 
 
 
 
 
14.2.2
HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.
 
 
 
 
 
 
14.2.3
POLYMEDICURE
 
 
 
 
 
 
14.2.4
UNION MEDICO INC.
 
 
 
 
 
 
14.2.5
SHL MEDICAL
 
 
 
 
 
 
14.2.6
ELCAM MEDICAL
 
 
 
 
15
COMPANY PROFILES: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View
 
 
 
 
 
868
 
15.1
KEY PLAYERS
 
 
 
 
 
 
 
15.1.1
JOHNSON & JOHNSON SERVICES, INC.
 
 
 
 
 
 
 
15.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
15.1.1.2
PRODUCTS OFFERED
 
 
 
 
 
 
15.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
15.1.1.3.1
PRODUCT LAUNCHES AND APPROVALS
 
 
 
 
 
 
15.1.1.3.2
DEALS
 
 
 
 
15.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
15.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
15.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
15.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
 
 
 
15.1.2
F. HOFFMANN-LA ROCHE LTD
 
 
 
 
 
 
15.1.3
PFIZER INC.
 
 
 
 
 
 
15.1.4
MERCK & CO., INC.
 
 
 
 
 
 
15.1.5
NOVARTIS AG
 
 
 
 
 
 
15.1.6
BAYER AG
 
 
 
 
 
 
15.1.7
ASTRAZENECA
 
 
 
 
 
 
15.1.8
TAKEDA PHARMACEUTICAL COMPANY LIMITED.
 
 
 
 
 
 
15.1.9
ELI LILLY AND COMPANY
 
 
 
 
 
 
15.1.10
AMGEN INC.
 
 
 
 
 
 
15.1.11
NOVO NORDISK A/S
 
 
 
 
 
 
15.1.12
REGENERON PHARMACEUTICALS INC.
 
 
 
 
 
 
15.1.13
FRESENIUS KABI AG
 
 
 
 
 
 
15.1.14
UCB S.A.
 
 
 
 
 
 
15.1.15
BIO-THERA SOLUTIONS, LTD.
 
 
 
 
 
15.2
OTHER PLAYERS
 
 
 
 
 
 
 
15.2.1
SAGENT
 
 
 
 
 
 
15.2.2
VALNEVA SE
 
 
 
 
 
 
15.2.3
XERIS PHARMACEUTICALS, INC.
 
 
 
 
 
 
15.2.4
PHARMAESSENTIA CORPORATION
 
 
 
 
 
 
15.2.5
HERON THERAPEUTICS, INC.
 
 
 
 
16
APPENDIX
 
 
 
 
 
958
 
16.1
DISCUSSION GUIDE
 
 
 
 
 
 
16.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
16.3
RELATED REPORTS
 
 
 
 
 
 
16.4
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
INJECTABLE DRUG DELIVERY MARKET: INCLUSIONS AND EXCLUSIONS
 
 
 
 
 
 
TABLE 2
STANDARD CURRENCY CONVERSION RATES (UNIT OF USD), 2021–2024
 
 
 
 
 
 
TABLE 3
INJECTABLE DRUG DELIVERY MARKET: STUDY ASSUMPTIONS
 
 
 
 
 
 
TABLE 4
INJECTABLE DRUG DELIVERY MARKET: RISK ASSESSMENT
 
 
 
 
 
 
TABLE 5
APPROVALS FOR AUTOINJECTOR BIOLOGICS BY US FDA, 2024
 
 
 
 
 
 
TABLE 6
KEY DEVELOPMENTS IN PREFILLED SYRINGES AND PEN INJECTORS, 2024–2025
 
 
 
 
 
 
TABLE 7
KEY BIOSIMILARS/GENERICS WITH INJECTABLE DRUG DELIVERY DEVICES
 
 
 
 
 
 
TABLE 8
AVERAGE SELLING PRICE TREND OF KEY PLAYER, BY DEVICE TYPE, 2022–2024 (USD)
 
 
 
 
 
 
TABLE 9
AVERAGE SELLING PRICE TREND OF PEN INJECTORS, BY REGION, 2022–2024 (USD)
 
 
 
 
 
 
TABLE 10
AVERAGE SELLING PRICE TREND OF NEEDLE-FREE INJECTORS, BY REGION, 2022–2024 (USD)
 
 
 
 
 
 
TABLE 11
AVERAGE SELLING PRICE TREND OF AUTOINJECTORS, BY REGION, 2022–2024 (USD)
 
 
 
 
 
 
TABLE 12
AVERAGE SELLING PRICE TREND OF WEARABLE INJECTORS, BY REGION, 2022–2024 (USD)
 
 
 
 
 
 
TABLE 13
INJECTABLE DRUG DELIVERY DEVICE PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
 
 
TABLE 14
INJECTABLE DRUG DELIVERY FORMULATION PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
 
 
 
 
 
 
TABLE 15
INJECTABLE DRUG DELIVERY MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023–2025
 
 
 
 
 
 
TABLE 16
IMPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021–2024 (USD THOUSAND)
 
 
 
 
 
 
TABLE 17
EXPORT DATA FOR HS CODE 901890 (INCLUDING AUTOINJECTORS), BY COUNTRY, 2021–2024 (USD THOUSAND)
 
 
 
 
 
 
TABLE 18
IMPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES), BY COUNTRY, 2021–2024 (USD THOUSAND)
 
 
 
 
 
 
TABLE 19
EXPORT DATA FOR HS CODE 90183100 (INCLUDING PREFILLED SYRINGES), BY COUNTRY, 2021–2024 (USD THOUSAND)
 
 
 
 
 
 
TABLE 20
INJECTABLE DRUG DELIVERY MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
 
 
 
 
 
 
TABLE 21
CASE STUDY 1: DEVELOPMENT OF CLASS III DRUG DELIVERY SYSTEM FOR CHEMOTHERAPY
 
 
 
 
 
 
TABLE 22
CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION
 
 
 
 
 
 
TABLE 23
CASE STUDY 3: ADOPTION OF PEN INJECTOR PLATFORMS FOR IMPROVED THERAPEUTIC OUTCOMES
 
 
 
 
 
 
TABLE 24
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 25
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 26
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 27
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 28
MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 29
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 30
INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 31
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
 
 
 
 
 
 
TABLE 32
INJECTABLE DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE, 2023–2027
 
 
 
 
 
 
TABLE 33
US ADJUSTED RECIPROCAL TARIFF RATES, 2024
 
 
 
 
 
 
TABLE 34
KEY PRODUCT-RELATED TARIFF EFFECTIVE INJECTABLE DRUG DELIVERY DEVICES
 
 
 
 
 
 
TABLE 35
NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
 
 
 
 
 
 
TABLE 36
ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
 
 
 
 
 
 
TABLE 37
EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS
 
 
 
 
 
 
TABLE 38
LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
 
 
 
 
 
 
TABLE 39
INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 40
INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 41
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY DEVICES
 
 
 
 
 
 
TABLE 42
INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 43
INJECTABLE DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 44
KEY PLAYERS PROVIDING CONVENTIONAL INJECTION DEVICES
 
 
 
 
 
 
TABLE 45
CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 46
CONVENTIONAL INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 47
CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 48
CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 49
KEY PLAYERS PROVIDING GLASS INJECTABLE DEVICES
 
 
 
 
 
 
TABLE 50
GLASS INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 51
KEY PLAYERS PROVIDING PLASTIC INJECTABLE DEVICES
 
 
 
 
 
 
TABLE 52
PLASTIC INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 53
CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 54
KEY PLAYERS PROVIDING FILLABLE SYRINGES
 
 
 
 
 
 
TABLE 55
FILLABLE SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 56
KEY PLAYERS PROVIDING PREFILLED SYRINGES
 
 
 
 
 
 
TABLE 57
PREFILLED SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 58
CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 59
KEY PLAYERS PROVIDING REUSABLE INJECTION DEVICES
 
 
 
 
 
 
TABLE 60
REUSABLE INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 61
KEY PLAYERS PROVIDING DISPOSABLE INJECTION DEVICES
 
 
 
 
 
 
TABLE 62
DISPOSABLE INJECTABLE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 63
KEY PLAYERS PROVIDING SELF-INJECTION DEVICES
 
 
 
 
 
 
TABLE 64
SELF-INJECTION DEVICES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 65
SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 66
SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 67
KEY PLAYERS PROVIDING NEEDLE-FREE INJECTORS
 
 
 
 
 
 
TABLE 68
NEEDLE-FREE INJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 69
NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 70
NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 71
KEY PLAYERS PROVIDING FILLABLE NEEDLE-FREE INJECTORS
 
 
 
 
 
 
TABLE 72
FILLABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 73
KEY PLAYERS PROVIDING PREFILLED NEEDLE-FREE INJECTORS
 
 
 
 
 
 
TABLE 74
PREFILLED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 75
NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 76
KEY PLAYERS PROVIDING JET-BASED NEEDLE-FREE INJECTORS
 
 
 
 
 
 
TABLE 77
JET-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 78
KEY PLAYERS PROVIDING SPRING-BASED NEEDLE-FREE INJECTORS
 
 
 
 
 
 
TABLE 79
SPRING-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 80
KEY PLAYERS PROVIDING LASER-POWERED NEEDLE-FREE INJECTORS
 
 
 
 
 
 
TABLE 81
LASER-POWERED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 82
VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 83
NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 84
KEY PLAYERS PROVIDING REUSABLE NEEDLE-FREE INJECTORS
 
 
 
 
 
 
TABLE 85
REUSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 86
KEY PLAYERS PROVIDING DISPOSABLE NEEDLE-FREE INJECTORS
 
 
 
 
 
 
TABLE 87
DISPOSABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 88
KEY PLAYERS PROVIDING AUTOINJECTORS
 
 
 
 
 
 
TABLE 89
AUTOINJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 90
AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 91
AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 92
KEY PLAYERS PROVIDING FILLABLE AUTOINJECTORS
 
 
 
 
 
 
TABLE 93
FILLABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 94
KEY PLAYERS PROVIDING PREFILLED AUTOINJECTORS
 
 
 
 
 
 
TABLE 95
PREFILLED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 96
AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 97
KEY PLAYERS PROVIDING AUTOMATED AUTOINJECTORS
 
 
 
 
 
 
TABLE 98
AUTOMATED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 99
KEY PLAYERS PROVIDING MANUAL AUTOINJECTORS
 
 
 
 
 
 
TABLE 100
MANUAL AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 101
AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 102
KEY PLAYERS PROVIDING STANDARDIZED AUTOINJECTORS
 
 
 
 
 
 
TABLE 103
STANDARDIZED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 104
KEY PLAYERS PROVIDING CUSTOMIZED AUTOINJECTORS
 
 
 
 
 
 
TABLE 105
CUSTOMIZED AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 106
AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 107
KEY PLAYERS PROVIDING REUSABLE AUTOINJECTORS
 
 
 
 
 
 
TABLE 108
REUSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 109
KEY PLAYERS PROVIDING DISPOSABLE AUTOINJECTORS
 
 
 
 
 
 
TABLE 110
DISPOSABLE AUTOINJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 111
KEY PLAYERS PROVIDING PEN INJECTORS
 
 
 
 
 
 
TABLE 112
PEN INJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 113
PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 114
PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 115
KEY PLAYERS PROVIDING SINGLE-CHAMBERED PEN INJECTORS
 
 
 
 
 
 
TABLE 116
SINGLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 117
KEY PLAYERS PROVIDING DOUBLE-CHAMBERED PEN INJECTORS
 
 
 
 
 
 
TABLE 118
DOUBLE-CHAMBERED PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 119
PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 120
KEY PLAYERS PROVIDING STANDARD PEN INJECTORS
 
 
 
 
 
 
TABLE 121
STANDARD PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 122
KEY PLAYERS PROVIDING CUSTOMIZED PEN INJECTORS
 
 
 
 
 
 
TABLE 123
CUSTOMIZED PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 124
PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 125
KEY PLAYERS PROVIDING REUSABLE PEN INJECTORS
 
 
 
 
 
 
TABLE 126
REUSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 127
KEY PLAYERS PROVIDING DISPOSABLE PEN INJECTORS
 
 
 
 
 
 
TABLE 128
DISPOSABLE PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 129
KEY PLAYERS PROVIDING WEARABLE INJECTORS
 
 
 
 
 
 
TABLE 130
WEARABLE INJECTORS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 131
WEARABLE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 132
KEY PLAYERS PROVIDING OTHER SELF-INJECTION DEVICES
 
 
 
 
 
 
TABLE 133
OTHER SELF-INJECTION DEVICES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
 
 
 
 
 
 
TABLE 134
OTHER SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 135
KEY PLAYERS PROVIDING FORMULATIONS
 
 
 
 
 
 
TABLE 136
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 137
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 138
KEY PLAYERS PROVIDING CONVENTIONAL DRUG DELIVERY FORMULATIONS
 
 
 
 
 
 
TABLE 139
CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 140
CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 141
KEY PLAYERS PROVIDING SOLUTIONS
 
 
 
 
 
 
TABLE 142
INJECTABLE DRUG DELIVERY SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 143
KEY PLAYERS PROVIDING RECONSTITUTED/LYOPHILIZED FORMULATIONS
 
 
 
 
 
 
TABLE 144
RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 145
KEY PLAYERS PROVIDING SUSPENSIONS
 
 
 
 
 
 
TABLE 146
INJECTABLE DRUG DELIVERY SUSPENSIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 147
KEY PLAYERS PROVIDING EMULSIONS
 
 
 
 
 
 
TABLE 148
INJECTABLE DRUG DELIVERY EMULSIONS MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 149
KEY PLAYERS PROVIDING NOVEL DRUG DELIVERY FORMULATIONS
 
 
 
 
 
 
TABLE 150
NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 151
NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 152
KEY PLAYERS PROVIDING COLLOIDAL DISPERSIONS
 
 
 
 
 
 
TABLE 153
COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 154
COLLOIDAL DISPERSIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 155
INJECTABLE DRUG DELIVERY NIOSOMES MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 156
KEY PLAYERS PROVIDING LIPOSOMES
 
 
 
 
 
 
TABLE 157
INJECTABLE DRUG DELIVERY LIPOSOMES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 158
KEY PLAYERS PROVIDING POLYMERIC/MIXED MICELLES
 
 
 
 
 
 
TABLE 159
INJECTABLE DRUG DELIVERY POLYMERIC/MIXED MICELLES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 160
INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 161
INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 162
KEY PLAYERS PROVIDING SOLID-LIPID NANOPARTICLES
 
 
 
 
 
 
TABLE 163
INJECTABLE DRUG DELIVERY SOLID-LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 164
KEY PLAYERS PROVIDING NANOSUSPENSIONS
 
 
 
 
 
 
TABLE 165
INJECTABLE DRUG DELIVERY NANOSUSPENSIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 166
KEY PLAYERS PROVIDING NANOEMULSIONS
 
 
 
 
 
 
TABLE 167
INJECTABLE DRUG DELIVERY NANOEMULSIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 168
KEY PLAYERS PROVIDING MICROPARTICLES
 
 
 
 
 
 
TABLE 169
INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 170
INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 171
KEY PLAYERS PROVIDING MICROSPHERES
 
 
 
 
 
 
TABLE 172
INJECTABLE DRUG DELIVERY MICROSPHERES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 173
KEY PLAYERS PROVIDING MICROCAPSULES
 
 
 
 
 
 
TABLE 174
INJECTABLE DRUG DELIVERY MICROCAPSULES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 175
KEY PLAYERS PROVIDING LONG-ACTING FORMULATIONS
 
 
 
 
 
 
TABLE 176
LONG-ACTING INJECTABLE FORMULATIONS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 177
INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 178
INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 179
INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 180
INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 181
INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 182
INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 183
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AUTOIMMUNE DISEASES
 
 
 
 
 
 
TABLE 184
INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 185
INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 186
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR RHEUMATOID ARTHRITIS
 
 
 
 
 
 
TABLE 187
INJECTABLE DRUG DELIVERY MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 188
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR MULTIPLE SCLEROSIS
 
 
 
 
 
 
TABLE 189
INJECTABLE DRUG DELIVERY MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 190
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR CROHN’S DISEASE
 
 
 
 
 
 
TABLE 191
INJECTABLE DRUG DELIVERY MARKET FOR CROHN’S DISEASE, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 192
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PSORIASIS
 
 
 
 
 
 
TABLE 193
INJECTABLE DRUG DELIVERY MARKET FOR PSORIASIS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 194
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OTHER AUTOIMMUNE DISEASES
 
 
 
 
 
 
TABLE 195
INJECTABLE DRUG DELIVERY MARKET FOR OTHER AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 196
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HORMONAL DISORDERS
 
 
 
 
 
 
TABLE 197
INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 198
INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 199
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR DIABETES
 
 
 
 
 
 
TABLE 200
INJECTABLE DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 201
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR REPRODUCTIVE HEALTH DISEASES
 
 
 
 
 
 
TABLE 202
INJECTABLE DRUG DELIVERY MARKET FOR REPRODUCTIVE HEALTH DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 203
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
 
 
 
 
 
 
TABLE 204
INJECTABLE DRUG DELIVERY MARKET FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 205
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OSTEOPOROSIS
 
 
 
 
 
 
TABLE 206
INJECTABLE DRUG DELIVERY MARKET FOR OSTEOPOROSIS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 207
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR GROWTH HORMONE DEFICIENCY
 
 
 
 
 
 
TABLE 208
INJECTABLE DRUG DELIVERY MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 209
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OBESITY
 
 
 
 
 
 
TABLE 210
INJECTABLE DRUG DELIVERY MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 211
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR CANCER
 
 
 
 
 
 
TABLE 212
INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 213
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR INFECTIOUS DISEASES
 
 
 
 
 
 
TABLE 214
INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 215
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ORPHAN DISEASES
 
 
 
 
 
 
TABLE 216
INJECTABLE DRUG DELIVERY MARKET FOR ORPHAN DISEASES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 217
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR OTHER THERAPEUTIC APPLICATIONS
 
 
 
 
 
 
TABLE 218
INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 219
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR PAIN MANAGEMENT
 
 
 
 
 
 
TABLE 220
INJECTABLE DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 221
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR ALLERGIES
 
 
 
 
 
 
TABLE 222
INJECTABLE DRUG DELIVERY MARKET FOR ALLERGIES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 223
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR AESTHETIC TREATMENTS
 
 
 
 
 
 
TABLE 224
INJECTABLE DRUG DELIVERY MARKET FOR AESTHETIC TREATMENTS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 225
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HEPATITIS C
 
 
 
 
 
 
TABLE 226
INJECTABLE DRUG DELIVERY MARKET FOR HEPATITIS C, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 227
KEY PLAYERS PROVIDING INJECTABLE DRUG DELIVERY PRODUCTS FOR HEMOPHILIA
 
 
 
 
 
 
TABLE 228
INJECTABLE DRUG DELIVERY MARKET FOR HEMOPHILIA, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 229
INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 230
INJECTABLE DRUG DELIVERY MARKET FOR CURATIVE CARE, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 231
INJECTABLE DRUG DELIVERY MARKET FOR IMMUNIZATION, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 232
INJECTABLE DRUG DELIVERY MARKET FOR OTHER USAGE PATTERNS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 233
INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 234
KEY PLAYERS PROVIDING DERMAL-BASED ADMINISTRATION
 
 
 
 
 
 
TABLE 235
INJECTABLE DRUG DELIVERY MARKET FOR DERMAL-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 236
KEY PLAYERS PROVIDING CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
 
 
 
 
 
 
TABLE 237
INJECTABLE DRUG DELIVERY MARKET FOR CIRCULATORY/MUSCULOSKELETAL-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 238
KEY PLAYERS PROVIDING ORGAN-BASED ADMINISTRATION
 
 
 
 
 
 
TABLE 239
INJECTABLE DRUG DELIVERY MARKET FOR ORGAN-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 240
KEY PLAYERS PROVIDING CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
 
 
 
 
 
 
TABLE 241
INJECTABLE DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 242
INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 243
INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 244
INJECTABLE DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 245
INJECTABLE DRUG DELIVERY MARKET FOR LONG-TERM CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 246
INJECTABLE DRUG DELIVERY MARKET FOR NURSING HOMES, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 247
INJECTABLE DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 248
INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 249
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 250
NORTH AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 251
NORTH AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 252
NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 253
NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 254
NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 255
NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 256
NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 257
NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 258
NORTH AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 259
NORTH AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 260
NORTH AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 261
NORTH AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 262
NORTH AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 263
NORTH AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 264
NORTH AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 265
NORTH AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 266
NORTH AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 267
NORTH AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 268
NORTH AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 269
NORTH AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 270
NORTH AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 271
NORTH AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 272
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 273
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 274
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 275
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 276
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 277
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 278
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 279
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 280
US: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 281
US: INJECTABLE DRUG DELIVERY MARKET PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 282
US: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 283
US: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 284
US: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 285
US: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 286
US: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 287
US: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 288
US: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 289
US: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 290
US: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 291
US: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 292
US: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 293
US: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 294
US: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 295
US: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 296
US: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 297
US: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 298
US: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 299
US: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 300
US: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 301
US: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 302
US: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 303
US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 304
US: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 305
US: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 306
US: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 307
US: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 308
US: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 309
US: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 310
US: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 311
CANADA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 312
CANADA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 313
CANADA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 314
CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 315
CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 316
CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 317
CANADA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 318
CANADA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 319
CANADA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 320
CANADA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 321
CANADA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 322
CANADA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 323
CANADA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 324
CANADA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 325
CANADA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 326
CANADA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 327
CANADA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 328
CANADA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 329
CANADA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 330
CANADA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 331
CANADA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 332
CANADA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 333
CANADA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 334
CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 335
CANADA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 336
CANADA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 337
CANADA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 338
CANADA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 339
CANADA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 340
CANADA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 341
CANADA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 342
EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 343
EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 344
EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 345
EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 346
EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 347
EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 348
EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 349
EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 350
EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 351
EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 352
EUROPE: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 353
EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 354
EUROPE: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 355
EUROPE: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 356
EUROPE: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 357
EUROPE: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 358
EUROPE: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 359
EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 360
EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 361
EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 362
EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 363
EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 364
EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 365
EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 366
EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 367
EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 368
EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 369
EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 370
EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 371
EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 372
EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 373
GERMANY: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 374
GERMANY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 375
GERMANY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 376
GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 377
GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 378
GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 379
GERMANY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 380
GERMANY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 381
GERMANY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 382
GERMANY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 383
GERMANY: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 384
GERMANY: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 385
GERMANY: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 386
GERMANY: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 387
GERMANY: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 388
GERMANY: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 389
GERMANY: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 390
GERMANY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 391
GERMANY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 392
GERMANY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 393
GERMANY: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 394
GERMANY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 395
GERMANY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 396
GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 397
GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 398
GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 399
GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 400
GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 401
GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 402
GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 403
GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 404
UK: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 405
UK: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 406
UK: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 407
UK: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 408
UK: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 409
UK: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 410
UK: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 411
UK: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 412
UK: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 413
UK: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 414
UK: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 415
UK: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 416
UK: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 417
UK: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 418
UK: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 419
UK: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 420
UK: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 421
UK: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 422
UK: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 423
UK: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 424
UK: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 425
UK: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 426
UK: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 427
UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 428
UK: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 429
UK: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 430
UK: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 431
UK: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 432
UK: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 433
UK: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 434
UK: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 435
FRANCE: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 436
FRANCE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 437
FRANCE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 438
FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 439
FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 440
FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 441
FRANCE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 442
FRANCE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 443
FRANCE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 444
FRANCE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 445
FRANCE: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 446
FRANCE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 447
FRANCE: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 448
FRANCE: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 449
FRANCE: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 450
FRANCE: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 451
FRANCE: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 452
FRANCE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 453
FRANCE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 454
FRANCE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 455
FRANCE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 456
FRANCE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 457
FRANCE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 458
FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 459
FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 460
FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 461
FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 462
FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 463
FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 464
FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 465
FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 466
SPAIN: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 467
SPAIN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 468
SPAIN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 469
SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 470
SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 471
SPAIN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 472
SPAIN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 473
SPAIN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 474
SPAIN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 475
SPAIN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 476
SPAIN: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 477
SPAIN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 478
SPAIN: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 479
SPAIN: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 480
SPAIN: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 481
SPAIN: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 482
SPAIN: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 483
SPAIN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 484
SPAIN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 485
SPAIN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 486
SPAIN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 487
SPAIN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 488
SPAIN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 489
SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 490
SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 491
SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 492
SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 493
SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 494
SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 495
SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 496
SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 497
ITALY: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 498
ITALY: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 499
ITALY: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 500
ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 501
ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 502
ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 503
ITALY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 504
ITALY: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 505
ITALY: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 506
ITALY: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 507
ITALY: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 508
ITALY: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 509
ITALY: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 510
ITALY: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 511
ITALY: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 512
ITALY: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 513
ITALY: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 514
ITALY: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 515
ITALY: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 516
ITALY: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 517
ITALY: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 518
ITALY: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 519
ITALY: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 520
ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 521
ITALY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 522
ITALY: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 523
ITALY: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 524
ITALY: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 525
ITALY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 526
ITALY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 527
ITALY: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 528
NETHERLANDS: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 529
NETHERLANDS: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 530
NETHERLANDS: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 531
NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 532
NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 533
NETHERLANDS: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 534
NETHERLANDS: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 535
NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 536
NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 537
NETHERLANDS: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 538
NETHERLANDS: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 539
NETHERLANDS: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 540
NETHERLANDS: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 541
NETHERLANDS: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 542
NETHERLANDS: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 543
NETHERLANDS: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 544
NETHERLANDS: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 545
NETHERLANDS: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 546
NETHERLANDS: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 547
NETHERLANDS: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 548
NETHERLANDS: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 549
NETHERLANDS: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 550
NETHERLANDS: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 551
NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 552
NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 553
NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 554
NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 555
NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 556
NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 557
NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 558
NETHERLANDS: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 559
REST OF EUROPE: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 560
REST OF EUROPE: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 561
REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 562
REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 563
REST OF EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 564
REST OF EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 565
REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 566
REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 567
REST OF EUROPE: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 568
REST OF EUROPE: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 569
REST OF EUROPE: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 570
REST OF EUROPE: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 571
REST OF EUROPE: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 572
REST OF EUROPE: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 573
REST OF EUROPE: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 574
REST OF EUROPE: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 575
REST OF EUROPE: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 576
REST OF EUROPE: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 577
REST OF EUROPE: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 578
REST OF EUROPE: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 579
REST OF EUROPE: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 580
REST OF EUROPE: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 581
REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 582
REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 583
REST OF EUROPE: INJECTABLE DRUG DELIVERY FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 584
REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 585
REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 586
REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 587
REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 588
REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 589
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 590
ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 591
ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 592
ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 593
ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 594
ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 595
ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 596
ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 597
ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 598
ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 599
ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 600
ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 601
ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 602
ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 603
ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 604
ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 605
ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 606
ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 607
ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 608
ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 609
ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 610
ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 611
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 612
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 613
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 614
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 615
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 616
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 617
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 618
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 619
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 620
CHINA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 621
CHINA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 622
CHINA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 623
CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 624
CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 625
CHINA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 626
CHINA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 627
CHINA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 628
CHINA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 629
CHINA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 630
CHINA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 631
CHINA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 632
CHINA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 633
CHINA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 634
CHINA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 635
CHINA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 636
CHINA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 637
CHINA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 638
CHINA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 639
CHINA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 640
CHINA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 641
CHINA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 642
CHINA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 643
CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 644
CHINA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 645
CHINA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 646
CHINA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 647
CHINA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 648
CHINA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 649
CHINA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 650
CHINA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 651
JAPAN: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 652
JAPAN: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 653
JAPAN: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 654
JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 655
JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 656
JAPAN: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 657
JAPAN: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 658
JAPAN: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 659
JAPAN: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 660
JAPAN: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 661
JAPAN: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 662
JAPAN: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 663
JAPAN: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 664
JAPAN: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 665
JAPAN: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 666
JAPAN: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 667
JAPAN: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 668
JAPAN: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 669
JAPAN: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 670
JAPAN: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 671
JAPAN: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 672
JAPAN: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 673
JAPAN: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 674
JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 675
JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 676
JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 677
JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 678
JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 679
JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 680
JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 681
JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 682
INDIA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 683
INDIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 684
INDIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 685
INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 686
INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 687
INDIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 688
INDIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 689
INDIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 690
INDIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 691
INDIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 692
INDIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 693
INDIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 694
INDIA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 695
INDIA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 696
INDIA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 697
INDIA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 698
INDIA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 699
INDIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 700
INDIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 701
INDIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 702
INDIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 703
INDIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 704
INDIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 705
INDIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 706
INDIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 707
INDIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 708
INDIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 709
INDIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 710
INDIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 711
INDIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 712
INDIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 713
AUSTRALIA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 714
AUSTRALIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 715
AUSTRALIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 716
AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 717
AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 718
AUSTRALIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 719
AUSTRALIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 720
AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 721
AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 722
AUSTRALIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 723
AUSTRALIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 724
AUSTRALIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 725
AUSTRALIA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 726
AUSTRALIA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 727
AUSTRALIA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 728
AUSTRALIA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 729
AUSTRALIA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 730
AUSTRALIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 731
AUSTRALIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 732
AUSTRALIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 733
AUSTRALIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 734
AUSTRALIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 735
AUSTRALIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 736
AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 737
AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 738
AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 739
AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 740
AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 741
AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 742
AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 743
AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 744
SOUTH KOREA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 745
SOUTH KOREA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 746
SOUTH KOREA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 747
SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 748
SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 749
SOUTH KOREA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 750
SOUTH KOREA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 751
SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 752
SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 753
SOUTH KOREA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 754
SOUTH KOREA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 755
SOUTH KOREA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 756
SOUTH KOREA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 757
SOUTH KOREA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 758
SOUTH KOREA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 759
SOUTH KOREA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 760
SOUTH KOREA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 761
SOUTH KOREA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 762
SOUTH KOREA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 763
SOUTH KOREA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 764
SOUTH KOREA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 765
SOUTH KOREA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 766
SOUTH KOREA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 767
SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 768
SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 769
SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 770
SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 771
SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 772
SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 773
SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 774
SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 775
THAILAND: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 776
THAILAND: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 777
THAILAND: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 778
THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 779
THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 780
THAILAND: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 781
THAILAND: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 782
THAILAND: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 783
THAILAND: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 784
THAILAND: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 785
THAILAND: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 786
THAILAND: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 787
THAILAND: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 788
THAILAND: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 789
THAILAND: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 790
THAILAND: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 791
THAILAND: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 792
THAILAND: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 793
THAILAND: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 794
THAILAND: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 795
THAILAND: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 796
THAILAND: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 797
THAILAND: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 798
THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 799
THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 800
THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 801
THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 802
THAILAND: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 803
THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 804
THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 805
THAILAND: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 806
VIETNAM: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 807
VIETNAM: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 808
VIETNAM: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 809
VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 810
VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 811
VIETNAM: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 812
VIETNAM: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 813
VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 814
VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 815
VIETNAM: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 816
VIETNAM: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 817
VIETNAM: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 818
VIETNAM: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 819
VIETNAM: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 820
VIETNAM: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 821
VIETNAM: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 822
VIETNAM: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 823
VIETNAM: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 824
VIETNAM: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 825
VIETNAM: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 826
VIETNAM: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 827
VIETNAM: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 828
VIETNAM: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 829
VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 830
VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 831
VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 832
VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 833
VIETNAM: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 834
VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 835
VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 836
VIETNAM: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 837
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 838
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 839
REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 840
REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 841
REST OF ASIA PACIFIC: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 842
REST OF ASIA PACIFIC: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 843
REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 844
REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 845
REST OF ASIA PACIFIC: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 846
REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 847
REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 848
REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 849
REST OF ASIA PACIFIC: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 850
REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 851
REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 852
REST OF ASIA PACIFIC: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 853
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 854
REST OF ASIA PACIFIC: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 855
REST OF ASIA PACIFIC: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 856
REST OF ASIA PACIFIC: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 857
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 858
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 859
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 860
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 861
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 862
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 863
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 864
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 865
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 866
REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 867
LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 868
LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 869
LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 870
LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 871
LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 872
LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 873
LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 874
LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 875
LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 876
LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 877
LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 878
LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 879
LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 880
LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 881
LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 882
LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 883
LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 884
LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 885
LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 886
LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 887
LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 888
LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 889
LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 890
LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 891
LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 892
LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 893
LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 894
LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 895
LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 896
LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 897
LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 898
BRAZIL: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 899
BRAZIL: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 900
BRAZIL: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 901
BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 902
BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 903
BRAZIL: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 904
BRAZIL: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 905
BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 906
BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 907
BRAZIL: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 908
BRAZIL: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 909
BRAZIL: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 910
BRAZIL: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 911
BRAZIL: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 912
BRAZIL: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 913
BRAZIL: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 914
BRAZIL: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 915
BRAZIL: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 916
BRAZIL: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 917
BRAZIL: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 918
BRAZIL: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 919
BRAZIL: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 920
BRAZIL: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 921
BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 922
BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 923
BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 924
BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 925
BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 926
BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 927
BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 928
BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 929
MEXICO: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 930
MEXICO: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 931
MEXICO: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 932
MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 933
MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 934
MEXICO: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 935
MEXICO: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 936
MEXICO: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 937
MEXICO: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 938
MEXICO: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 939
MEXICO: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 940
MEXICO: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 941
MEXICO: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 942
MEXICO: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 943
MEXICO: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 944
MEXICO: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 945
MEXICO: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 946
MEXICO: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 947
MEXICO: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 948
MEXICO: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 949
MEXICO: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 950
MEXICO: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 951
MEXICO: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 952
MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 953
MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 954
MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 955
MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 956
MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 957
MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 958
MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 959
MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 960
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 961
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 962
REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 963
REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 964
REST OF LATIN AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 965
REST OF LATIN AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 966
REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 967
REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 968
REST OF LATIN AMERICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 969
REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 970
REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 971
REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 972
REST OF LATIN AMERICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 973
REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 974
REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 975
REST OF LATIN AMERICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 976
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 977
REST OF LATIN AMERICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 978
REST OF LATIN AMERICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 979
REST OF LATIN AMERICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 980
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 981
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 982
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 983
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 984
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 985
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 986
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 987
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 988
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 989
REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 990
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 991
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 992
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 993
MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 994
MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 995
MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 996
MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 997
MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 998
MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 999
MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1000
MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1001
MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1002
MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1003
MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1004
MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1005
MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1006
MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1007
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1008
MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1009
MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1010
MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1011
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1012
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1013
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1014
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1015
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1016
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1017
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1018
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1019
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1020
MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1021
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1022
GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1023
GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1024
GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1025
GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1026
GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1027
GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1028
GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1029
GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1030
GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1031
GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1032
GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1033
GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1034
GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1035
GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1036
GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1037
GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1038
GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1039
GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1040
GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1041
GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1042
GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1043
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1044
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1045
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1046
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1047
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1048
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1049
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1050
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1051
GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1052
SAUDI ARABIA: KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 1053
SAUDI ARABIA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1054
SAUDI ARABIA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1055
SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1056
SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1057
SAUDI ARABIA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1058
SAUDI ARABIA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1059
SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1060
SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1061
SAUDI ARABIA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1062
SAUDI ARABIA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1063
SAUDI ARABIA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1064
SAUDI ARABIA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1065
SAUDI ARABIA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1066
SAUDI ARABIA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1067
SAUDI ARABIA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1068
SAUDI ARABIA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1069
SAUDI ARABIA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1070
SAUDI ARABIA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1071
SAUDI ARABIA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1072
SAUDI ARABIA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1073
SAUDI ARABIA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1074
SAUDI ARABIA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1075
SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1076
SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1077
SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1078
SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1079
SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1080
SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1081
SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1082
SAUDI ARABIA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1083
UNITED ARAB EMIRATES (UAE): KEY MACROECONOMIC INDICATORS
 
 
 
 
 
 
TABLE 1084
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1085
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1086
UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1087
UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1088
UNITED ARAB EMIRATES (UAE): CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1089
UNITED ARAB EMIRATES (UAE): SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1090
UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1091
UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1092
UNITED ARAB EMIRATES (UAE): NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1093
UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1094
UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1095
UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1096
UNITED ARAB EMIRATES (UAE): AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1097
UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1098
UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1099
UNITED ARAB EMIRATES (UAE): PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1100
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1101
UNITED ARAB EMIRATES (UAE): CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1102
UNITED ARAB EMIRATES (UAE): NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1103
UNITED ARAB EMIRATES (UAE): COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1104
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1105
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1106
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1107
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1108
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1109
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1110
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1111
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1112
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1113
UNITED ARAB EMIRATES (UAE): INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1114
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1115
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1116
REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1117
REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1118
REST OF GCC COUNTRIES: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1119
REST OF GCC COUNTRIES: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1120
REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1121
REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1122
REST OF GCC COUNTRIES: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1123
REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1124
REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1125
REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1126
REST OF GCC COUNTRIES: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1127
REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1128
REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1129
REST OF GCC COUNTRIES: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1130
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1131
REST OF GCC COUNTRIES: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1132
REST OF GCC COUNTRIES: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1133
REST OF GCC COUNTRIES: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1134
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1135
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1136
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1137
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1138
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1139
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1140
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1141
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1142
REST OF GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1143
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1144
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY PRODUCTS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1145
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1146
REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1147
REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1148
REST OF MIDDLE EAST & AFRICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1149
REST OF MIDDLE EAST & AFRICA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1150
REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1151
REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1152
REST OF MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1153
REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1154
REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY TECHNOLOGY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1155
REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1156
REST OF MIDDLE EAST & AFRICA: AUTOINJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1157
REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1158
REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY DESIGN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1159
REST OF MIDDLE EAST & AFRICA: PEN INJECTORS MARKET, BY USABILITY, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1160
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1161
REST OF MIDDLE EAST & AFRICA: CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1162
REST OF MIDDLE EAST & AFRICA: NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1163
REST OF MIDDLE EAST & AFRICA: COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1164
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY NANOPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1165
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MICROPARTICLES MARKET, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1166
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1167
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1168
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1169
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1170
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1171
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1172
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1173
REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
 
 
 
 
 
 
TABLE 1174
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INJECTABLE DRUG DELIVERY MARKET
 
 
 
 
 
 
TABLE 1175
INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 1176
INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 1177
INJECTABLE DRUG DELIVERY DEVICES MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 1178
INJECTABLE DRUG DELIVERY DEVICES MARKET: PRODUCT TYPE FOOTPRINT
 
 
 
 
 
 
TABLE 1179
INJECTABLE DRUG DELIVERY DEVICES MARKET: USAGE PATTERN FOOTPRINT
 
 
 
 
 
 
TABLE 1180
INJECTABLE DRUG DELIVERY DEVICES MARKET: THERAPEUTIC APPLICATION FOOTPRINT
 
 
 
 
 
 
TABLE 1181
INJECTABLE DRUG DELIVERY DEVICES MARKET: SITE OF ADMINISTRATION FOOTPRINT
 
 
 
 
 
 
TABLE 1182
INJECTABLE DRUG DELIVERY DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 1183
INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 1184
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 1185
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: PRODUCT TYPE FOOTPRINT
 
 
 
 
 
 
TABLE 1186
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: FORMULATION PACKAGING FOOTPRINT
 
 
 
 
 
 
TABLE 1187
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: THERAPEUTIC APPLICATION FOOTPRINT
 
 
 
 
 
 
TABLE 1188
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: SITE OF ADMINISTRATION TYPE FOOTPRINT
 
 
 
 
 
 
TABLE 1189
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 1190
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
 
 
 
 
 
 
TABLE 1191
INJECTABLE DRUG DELIVERY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1192
INJECTABLE DRUG DELIVERY MARKET: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1193
INJECTABLE DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1194
CARDINAL HEALTH: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1195
CARDINAL HEALTH: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1196
CARDINAL HEALTH: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1197
BD: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1198
BD: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1199
BD: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1200
BD: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1201
B. BRAUN SE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1202
B. BRAUN SE: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1203
BAXTER: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1204
BAXTER: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1205
BAXTER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1206
TERUMO CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1207
TERUMO CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1208
TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1209
TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1210
PHILLIPS-MEDSIZE CORPORATION (MOLEX): COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1211
PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1212
PHILLIPS-MEDSIZE CORPORATION (MOLEX): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1213
PHILLIPS-MEDSIZE CORPORATION (MOLEX): DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1214
PHILLIPS-MEDSIZE CORPORATION (MOLEX): EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1215
NIPRO: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1216
NIPRO: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1217
NIPRO: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1218
ICU MEDICAL, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1219
ICU MEDICAL, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1220
ICU MEDICAL, INC.: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1221
WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1222
WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1223
WEST PHARMACEUTICAL SERVICES, INC.: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1224
WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1225
GERRESHEIMER AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1226
GERRESHEIMER AG: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1227
GERRESHEIMER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1228
GERRESHMEIMER AG: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1229
GERRESHMEIMER AG: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1230
STEVANATO: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1231
STEVANATO: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1232
STEVANATO: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1233
STEVANATO: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1234
STEVANATO: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1235
SCHOTT PHARMA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1236
SCHOTT PHARMA: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1237
SCHOTT PHARMA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1238
SCHOTT PHARMA: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1239
SCOTT PHARMA: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1240
MEDMIX: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1241
MEDMIX: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1242
MEDMIX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1243
MEDMIX: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1244
SOLM: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1245
SOLM: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1246
YPSOMED: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1247
YPSOMED: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1248
YPSOMED: DEALS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1249
YPSOMED: EXPANSIONS, JANUARY 2022–MARCH 2025
 
 
 
 
 
 
TABLE 1250
OWEN MUMFORD: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1251
HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1252
POLYMEDICURE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1253
UNION MEDICO INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1254
SHL MEDICAL: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1255
ELCAM MEDICAL: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1256
JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1257
JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1258
JOHNSON & JOHNSON SERVICES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1259
JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1260
F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1261
F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1262
F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1263
PFIZER INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1264
PFIZER INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1265
PFIZER INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1266
PFIZER INC.: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1267
MERCK & CO., INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1268
MERCK & CO., INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1269
MERCK & CO., INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1270
MERCK & CO., INC.: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1271
MERCK & CO., INC.: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1272
NOVARTIS AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1273
NOVARTIS AG: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1274
NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1275
NOVARTIS AG: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1276
NOVARTIS AG: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1277
BAYER AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1278
BAYER AG: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1279
BAYER AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1280
BAYER AG: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1281
ASTRAZENECA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1282
ASTRAZENECA: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1283
ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1284
ASTRAZENECA: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1285
ASTRAZENECA: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1286
TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1287
TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1288
TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1289
TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1290
TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1291
ELI LILLY AND COMPANY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1292
ELI LILLY AND COMPANY: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1293
ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1294
ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1295
AMGEN INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1296
AMGEN INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1297
AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1298
AMGEN INC.: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1299
AMGEN INC.: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1300
NOVO NORDISK A/S: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1301
NOVO NORDISK A/S: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1302
NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1303
NOVO NORDISK A/S: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1304
NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1305
REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1306
REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1307
REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1308
REGENERON PHARMACEUTICALS INC.: DEALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1309
FRESENIUS KABI AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1310
FRESENIUS KABI AG: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1311
FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1312
UCB S.A.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1313
UCB S.A.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1314
UCB S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1315
BIO-THERA SOLUTIONS, LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1316
BIO-THERA SOLUTIONS, LTD.: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 1317
BIO-THERA SOLUTIONS, LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025
 
 
 
 
 
 
TABLE 1318
SAGENT: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1319
VALNEVA SE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1320
XERIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1321
PHARMAESSENTIA CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 1322
HERON THERAPEUTICS, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
INJECTABLE DRUG DELIVERY MARKET SEGMENTATION
 
 
 
 
 
 
FIGURE 2
INJECTABLE DRUG DELIVERY MARKET REGIONAL SEGMENTATION
 
 
 
 
 
 
FIGURE 3
INJECTABLE DRUG DELIVERY MARKET: RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
 
 
 
 
 
 
FIGURE 5
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 6
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
 
 
 
 
 
 
FIGURE 7
MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
 
 
 
 
 
 
FIGURE 8
INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
 
 
 
 
 
 
FIGURE 9
TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 10
BOTTOM-UP APPROACH
 
 
 
 
 
 
FIGURE 11
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 
FIGURE 12
INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
 
 
 
 
 
 
FIGURE 13
INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2025 VS. 2030 (USD BILLION)
 
 
 
 
 
 
FIGURE 14
INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2025 VS. 2030 (USD BILLION)
 
 
 
 
 
 
FIGURE 15
INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2025 VS. 2030 (USD BILLION)
 
 
 
 
 
 
FIGURE 16
INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
 
 
 
 
 
 
FIGURE 17
INJECTABLE DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
 
 
 
 
 
 
FIGURE 18
INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT
 
 
 
 
 
 
FIGURE 19
RISING CHRONIC DISEASES TO DRIVE MARKET
 
 
 
 
 
 
FIGURE 20
DEVICES SEGMENT AND US DOMINATED NORTH AMERICAN INJECTABLE DRUG DELIVERY MARKET IN 2024
 
 
 
 
 
 
FIGURE 21
ASIA PACIFIC TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 22
CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 23
DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 24
INJECTABLE DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 25
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
FIGURE 26
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PEN INJECTORS (INSULIN PENS), 2024 (USD)
 
 
 
 
 
 
FIGURE 27
INJECTABLE DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 28
INJECTABLE DRUG DELIVERY MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 29
INJECTABLE DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 30
INJECTABLE DRUG DELIVERY MARKET: INVESTMENT AND FUNDING SCENARIO, 2021–2023
 
 
 
 
 
 
FIGURE 31
INJECTABLE DRUG DELIVERY MARKET: PATENT ANALYSIS, JANUARY 2014–MARCH 2025
 
 
 
 
 
 
FIGURE 32
TOP APPLICANTS FOR INJECTABLE DRUG DELIVERY PATENTS, JANUARY 2014–MARCH 2025
 
 
 
 
 
 
FIGURE 33
INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 34
KEY STAKEHOLDERS IN BUYING PROCESS FOR HOSPITALS & CLINICS (INJECTABLE DRUG DELIVERY DEVICES)
 
 
 
 
 
 
FIGURE 35
BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY DEVICES FOR TOP THREE END USERS
 
 
 
 
 
 
FIGURE 36
KEY BUYING CRITERIA FOR INJECTABLE DRUG DELIVERY WITH FORMULATIONS FOR TOP THREE END USERS
 
 
 
 
 
 
FIGURE 37
TOTAL NUMBER OF TRIALS COMPLETED/YEAR, 2024–2032
 
 
 
 
 
 
FIGURE 38
AI USE CASES
 
 
 
 
 
 
FIGURE 39
INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC SNAPSHOT, 2024
 
 
 
 
 
 
FIGURE 40
NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 41
ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 42
REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2022−2024
 
 
 
 
 
 
FIGURE 43
REVENUE ANALYSIS OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2022−2024
 
 
 
 
 
 
FIGURE 44
MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024
 
 
 
 
 
 
FIGURE 45
RANKING OF KEY INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS, 2024
 
 
 
 
 
 
FIGURE 46
MARKET SHARE ANALYSIS OF INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2024
 
 
 
 
 
 
FIGURE 47
RANKING OF KEY INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2024
 
 
 
 
 
 
FIGURE 48
INJECTABLE DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
FIGURE 49
R&D EXPENDITURE OF KEY PLAYERS IN INJECTABLE DRUG DELIVERY MARKET, 2022−2024
 
 
 
 
 
 
FIGURE 50
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 51
YEAR-TO-YEAR (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 52
INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
 
 
 
 
 
 
FIGURE 53
INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 54
INJECTABLE DRUG DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
 
 
FIGURE 55
INJECTABLE DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX, 2024
 
 
 
 
 
 
FIGURE 56
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 57
INJECTABLE DRUG DELIVERY FORMULATIONS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
 
 
 
 
 
 
FIGURE 58
CARDINAL HEALTH: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 59
BD: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 60
B. BRAUN SE: COMPANY SNAPSHOT (2023)
 
 
 
 
 
 
FIGURE 61
BAXTER: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 62
TERUMO CORPORATION: COMPANY SNAPSHOT (2023)
 
 
 
 
 
 
FIGURE 63
NIPRO: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 64
ICU MEDICAL, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 65
WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 66
GERRESHEIMER AG: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 67
STEVANATO: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 68
SCHOTT PHARMA: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 69
MEDMIX: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 70
YPSOMED: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 71
JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 72
F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 73
PFIZER INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 74
MERCK & CO., INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 75
NOVARTIS AG: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 76
BAYER AG: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 77
ASTRAZENECA: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 78
TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 79
ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 80
AMGEN INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 81
NOVO NORDISK A/S: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 82
REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 83
FRESENIUS KABI AG: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 84
UCB S.A.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 85
BIO-THERA SOLUTIONS, LTD.: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 

Methodology

This study extensively used both primary and secondary sources. The research process involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the injectable drug delivery market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the injectable drug delivery markets. Primary sources from the demand side include healthcare professionals from hospitals, nursing care facilities, long-term health centers, and ambulatory surgical centers.

A breakdown of the primary respondents is provided below:

Injectable Drug Delivery Market

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the injectable drug delivery market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Injectable Drug Delivery Market

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

The injectable drug delivery market encompasses products, technologies, and services involved in the administration of drugs through injections. It includes a broad range of devices such as conventional syringes, auto-injectors, pen injectors, prefilled syringes, and wearable injectors, as well as various formulations like solutions, suspensions, and emulsions specifically designed for injections. This market addresses the delivery of biologics, vaccines, insulin, cancer therapies, and other treatments requiring precise and rapid drug absorption. It caters to diverse settings, including hospitals, clinics, home care, and ambulatory centers.

Stakeholders

  • Injectable Drug and Device Manufacturing Companies
  • Pharmaceutical & Injectable Drug Manufacturing Companies
  • Healthcare Institutions (Hospitals & Outpatient Clinics)
  • Distributors and Suppliers of Injectable Drugs & Devices
  • Research Institutes
  • Health Insurance Payers
  • Market Research and Consulting Firms

Report Objectives

  • To define, describe, segment, and forecast the injectable drug delivery market by product, therapeutic application, usage pattern, site of administration, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall injectable drug delivery market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the injectable drug delivery market in six main regions (along with their respective key countries), namely, North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC countries
  • To profile the key players in the injectable drug delivery market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

 

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Injectable Drug Delivery Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Injectable Drug Delivery Market

DMCA.com Protection Status